OBJECTIVE/HYPOTHESIS: Therapeutic agents that enhance mucociliary transport (via stimulation of transepithelial Cl- secretion) and inhibit inflammation could provide considerable advantages over conventional treatments for chronic rhinosinusitis (CRS). The objectives of the present study were to investigate whether the polyphenolic compound resveratrol promotes transepithelial Cl- transport and inhibits KC/IL-8 secretion in sinonasal epithelium. STUDY DESIGN: In vitro and in vivo study. METHODS: Transepithelial Cl- transport was investigated in primary murine nasal septal (MNSE) and human sinonasal epithelial (HSNE) cultures. In vivo activity was also measured using the murine nasal potential difference assay. CFTR R-domain phosphorylation and cAMP levels were examined as a test of cAMP/PKA-dependent activation. In vitro LPS-induced KC/IL-8 secretion was quantified and compared to a panel of intranasal steroids. RESULTS: Resveratrol(100 μM) significantly increased CFTR-mediated Cl- transport (change in short-circuit current, ΔI(SC) ) in both MNSE (13.51 ± 0.77 vs. 4.4 ± 0.66 [control]; P < .05) and HSNE (12.28 ± 1.08 vs. 0.69 ± 0.32 [control]; P < .05). Cl- secretion across in vivo murine nasal epithelium was also enhanced (-4 ± 1.8 vs. -0.8 ± 1.7mV [control], P < .05). There was no increase in cellular cAMP or CFTR R-domain phosphorylation detected. Resveratrol also significantly inhibited KC/IL-8 secretion in a dose-dependent fashion (pg/mL) in MNSE (181 ± 39[100 μM) vs. 94 ± 16 [200 μM] vs. 16 ± 22 [500 μM] vs. 1195 ± 355 [LPS control]; P < .001). The compound robustly abrogated KC/IL-8 secretion when compared to ciclesonide (765 ± 139), triamcinolone (561 ± 124), and budesonide (742 ± 428), but had similar activity to fluticasone proprionate (65 ± 47). Similar effects were demonstrated in HSNE (975 ± 244 [100 μM] vs. 1825 ± 144 [LPS control]; P < .001) with inhibition comparable to fluticasone proprionate (785 ± 277). CONCLUSIONS: These in vitro and in vivo findings indicate resveratrol is a potent Cl- secretagogue and anti-inflammatory agent. Future clinical trials for CRS are warranted.
OBJECTIVE/HYPOTHESIS: Therapeutic agents that enhance mucociliary transport (via stimulation of transepithelial Cl- secretion) and inhibit inflammation could provide considerable advantages over conventional treatments for chronic rhinosinusitis (CRS). The objectives of the present study were to investigate whether the polyphenolic compound resveratrol promotes transepithelial Cl- transport and inhibits KC/IL-8 secretion in sinonasal epithelium. STUDY DESIGN: In vitro and in vivo study. METHODS: Transepithelial Cl- transport was investigated in primary murine nasal septal (MNSE) and human sinonasal epithelial (HSNE) cultures. In vivo activity was also measured using the murine nasal potential difference assay. CFTR R-domain phosphorylation and cAMP levels were examined as a test of cAMP/PKA-dependent activation. In vitro LPS-induced KC/IL-8 secretion was quantified and compared to a panel of intranasal steroids. RESULTS:Resveratrol(100 μM) significantly increased CFTR-mediated Cl- transport (change in short-circuit current, ΔI(SC) ) in both MNSE (13.51 ± 0.77 vs. 4.4 ± 0.66 [control]; P < .05) and HSNE (12.28 ± 1.08 vs. 0.69 ± 0.32 [control]; P < .05). Cl- secretion across in vivo murine nasal epithelium was also enhanced (-4 ± 1.8 vs. -0.8 ± 1.7mV [control], P < .05). There was no increase in cellular cAMP or CFTR R-domain phosphorylation detected. Resveratrol also significantly inhibited KC/IL-8 secretion in a dose-dependent fashion (pg/mL) in MNSE (181 ± 39[100 μM) vs. 94 ± 16 [200 μM] vs. 16 ± 22 [500 μM] vs. 1195 ± 355 [LPS control]; P < .001). The compound robustly abrogated KC/IL-8 secretion when compared to ciclesonide (765 ± 139), triamcinolone (561 ± 124), and budesonide (742 ± 428), but had similar activity to fluticasone proprionate (65 ± 47). Similar effects were demonstrated in HSNE (975 ± 244 [100 μM] vs. 1825 ± 144 [LPS control]; P < .001) with inhibition comparable to fluticasone proprionate (785 ± 277). CONCLUSIONS: These in vitro and in vivo findings indicate resveratrol is a potent Cl- secretagogue and anti-inflammatory agent. Future clinical trials for CRS are warranted.
Authors: Christopher Azbell; Shaoyan Zhang; Daniel Skinner; James Fortenberry; Eric J Sorscher; Bradford A Woodworth Journal: Otolaryngol Head Neck Surg Date: 2010-09 Impact factor: 3.497
Authors: Frank Virgin; Shaoyan Zhang; Daniel Schuster; Christopher Azbell; James Fortenberry; Eric J Sorscher; Bradford A Woodworth Journal: Laryngoscope Date: 2010-05 Impact factor: 3.325
Authors: Frank W Virgin; Christopher Azbell; Daniel Schuster; Jumin Sunde; Shaoyan Zhang; Eric J Sorscher; Bradford A Woodworth Journal: Laryngoscope Date: 2010-07 Impact factor: 3.325
Authors: Louise C Pyle; Jennifer C Fulton; Peter A Sloane; Kyle Backer; Marina Mazur; Jeevan Prasain; Stephen Barnes; J P Clancy; Steven M Rowe Journal: Am J Respir Cell Mol Biol Date: 2009-12-30 Impact factor: 6.914
Authors: Noam A Cohen; Shaoyan Zhang; Dawn B Sharp; Edwin Tamashiro; Bei Chen; Eric J Sorscher; Bradford A Woodworth Journal: Laryngoscope Date: 2009-11 Impact factor: 3.325
Authors: Frank J Accurso; Steven M Rowe; J P Clancy; Michael P Boyle; Jordan M Dunitz; Peter R Durie; Scott D Sagel; Douglas B Hornick; Michael W Konstan; Scott H Donaldson; Richard B Moss; Joseph M Pilewski; Ronald C Rubenstein; Ahmet Z Uluer; Moira L Aitken; Steven D Freedman; Lynn M Rose; Nicole Mayer-Hamblett; Qunming Dong; Jiuhong Zha; Anne J Stone; Eric R Olson; Claudia L Ordoñez; Preston W Campbell; Melissa A Ashlock; Bonnie W Ramsey Journal: N Engl J Med Date: 2010-11-18 Impact factor: 176.079
Authors: Do-Yeon Cho; Daniel Skinner; Shaoyan Zhang; James Fortenberry; Eric J Sorscher; Nichole R Dean; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2015-12-03 Impact factor: 3.858
Authors: Nathan S Alexander; Angela Blount; Shaoyan Zhang; Daniel Skinner; Stephen B Hicks; Michael Chestnut; Frederick A Kebbel; Eric J Sorscher; Bradford A Woodworth Journal: Laryngoscope Date: 2012-04-20 Impact factor: 3.325
Authors: Elisa A Illing; Do-Yeon Cho; Shaoyan Zhang; Daniel F Skinner; Quinn A Dunlap; Eric J Sorscher; Bradford A Woodworth Journal: Otolaryngol Head Neck Surg Date: 2015-05-27 Impact factor: 3.497
Authors: Nichole Dean; Neel K Ranganath; Brandon Jones; Shaoyan Zhang; Daniel Skinner; Steven M Rowe; Eric J Sorscher; Bradford A Woodworth Journal: Int Forum Allergy Rhinol Date: 2014-04-14 Impact factor: 3.858
Authors: Bryant T Conger; Shaoyan Zhang; Daniel Skinner; Stephen B Hicks; Eric J Sorscher; Steven M Rowe; Bradford A Woodworth Journal: JAMA Otolaryngol Head Neck Surg Date: 2013-08-01 Impact factor: 6.223
Authors: Shaoyan Zhang; Neel K Ranganath; Daniel Skinner; David M Bedwell; Jessica A Buckley-Lanier; Eric J Sorscher; Bradford A Woodworth Journal: J Cyst Fibros Date: 2013-12-27 Impact factor: 5.482